United Therapeutics Corporation(UTHR)Earnings, Financials & Key Ratios

UTHR•NASDAQ

$596.13

$26.13B mkt cap·21.4× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Show more

Revenue$3.18B+10.6%
EBITDA$1.58B+8.9%
Net Income$1.33B+11.7%
EPS (Diluted)27.86+13.1%
Gross Margin87.92%-1.5%
EBITDA Margin49.58%-1.6%
Operating Margin46.89%-2.0%
Net Margin41.94%+1.0%
ROE19.71%+2.5%
ROIC21.15%+7.8%
Interest Coverage88.89+141.1%

Analysis→Technical→

UTHR Key Insights

United Therapeutics Corporation (UTHR) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong 5Y profit CAGR of 21.0%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 32.7% free cash flow margin
✓Momentum leader: RS Rating 84 (top 16%)
✓Strong 5Y sales CAGR of 16.5%
✓Good 3Y average ROE of 19.1%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

UTHR Price & Volume

United Therapeutics Corporation (UTHR) stock price & volume — 10-year historical chart

Loading chart...

UTHR Growth Metrics

United Therapeutics Corporation (UTHR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years8.06%

5 Years16.5%

3 Years18.02%

TTM5.87%

Profit CAGR

10 Years7.43%

5 Years20.99%

3 Years22.43%

TTM6.34%

EPS CAGR

10 Years8.16%

5 Years19.28%

3 Years22.92%

TTM7.94%

Return on Capital

10 Years22.52%

5 Years18.59%

3 Years20.75%

Last Year21.41%

UTHR Recent Earnings

United Therapeutics Corporation (UTHR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 6, 2026

EPS

$6.32

Est $7.00

-9.7%

Revenue

$782M

Est $797M

-2.0%

Q1 2026

Feb 25, 2026

EPS

$7.70

Est $7.13

+8.0%

Revenue

$790M

Est $813M

-2.8%

Q4 2025

Oct 29, 2025

EPS

$7.16

Est $6.89

+3.9%

Revenue

$800M

Est $815M

-1.9%

Q3 2025

Jul 30, 2025

EPS

$6.41

Est $7.29

-12.1%

Revenue

$799M

Est $802M

-0.4%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 6, 2026	$6.32vs $7.00-9.7%	$782Mvs $797M-2.0%
Q1 2026	Feb 25, 2026	$7.70vs $7.13+8.0%	$790Mvs $813M-2.8%
Q4 2025	Oct 29, 2025	$7.16vs $6.89+3.9%	$800Mvs $815M-1.9%
Q3 2025	Jul 30, 2025	$6.41vs $7.29-12.1%	$799Mvs $802M-0.4%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
IDYAIDEAYA Biosciences, Inc.Direct Competitor	2.52B	28.74	-22.45	30.24%	-62.17%	-13.96%	0.03
RAREUltragenyx Pharmaceutical Inc.Direct Competitor	2.55B	25.93	-4.45	20.13%	-91.03%	-6.08%
ACADACADIA Pharmaceuticals Inc.Direct Competitor	3.68B	21.48	9.38	11.87%	36.49%	41.9%	0.04
PTGXProtagonist Therapeutics, Inc.Direct Competitor	6.63B	103.97	-50.72	-89.41%	-6.48%	-17.76%	0.02
INVAInnoviva, Inc.Direct Competitor	1.91B	22.52	6.82	18.52%	118.91%	46.47%	0.23
HALOHalozyme Therapeutics, Inc.Direct Competitor	7.81B	66.35	25.92	37.55%	22.69%	6.49%
MNKDMannKind CorporationProduct Competitor	1.1B	3.56	178	22.23%	-6.63%
LNTHLantheus Holdings, Inc.Product Competitor	5.61B	86.15	25.26	0.5%	15.15%	20.58%	0.00

Compare UTHR vs Peers

United Therapeutics Corporation (UTHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IDYA

Most directly comparable listed peer for UTHR.

Scale Benchmark

vs MCK

Larger-name benchmark to compare UTHR against a more recognizable public peer.

Peer Set

Compare Top 5

vs IDYA, RARE, ACAD, PTGX

UTHR Income Statement

United Therapeutics Corporation (UTHR) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	1.73B	1.63B	1.45B	1.48B	1.69B	1.94B	2.33B	2.88B	3.18B	3.17B
Revenue Growth %	7.91%	-5.65%	-11%	2.38%	13.63%	14.88%	20.2%	23.63%	10.61%	5.87%
Cost of Goods Sold	105.7M	198.7M	117.6M	108.1M	122.5M	146.7M	257.5M	309.7M	384.4M	425.3M
COGS % of Revenue	6.13%	12.21%	8.12%	7.29%	7.27%	7.58%	11.06%	10.76%	12.08%	-
Gross Profit	1.62B▲ 0%	1.43B▼ 11.8%	1.33B▼ 6.9%	1.38B▲ 3.3%	1.56B▲ 13.7%	1.79B▲ 14.5%	2.07B▲ 15.7%	2.57B▲ 24.0%	2.8B▲ 9.0%	2.74B▲ 0%
Gross Margin %	93.87%	87.79%	91.88%	92.71%	92.73%	92.42%	88.94%	89.24%	87.92%	86.58%
Gross Profit Growth %	6.13%	-11.76%	-6.85%	3.31%	13.66%	14.5%	15.67%	24.04%	8.98%	-
Operating Expenses	594.7M	623.7M	1.52B	781.6M	1.01B	809.9M	885.1M	1.19B	1.31B	1.31B
OpEx % of Revenue	34.47%	38.32%	104.83%	52.69%	59.75%	41.83%	38.03%	41.38%	41.03%	-
Selling, General & Admin	330.1M	265.8M	336.2M	423.9M	467M	487M	477.1M	638.6M	755.8M	769.8M
SG&A % of Revenue	19.13%	16.33%	23.21%	28.58%	27.71%	25.15%	20.5%	22.19%	23.75%	-
Research & Development	264.6M	357.9M	1.18B	357.7M	540.1M	322.9M	408M	481M	550M	539.2M
R&D % of Revenue	15.34%	21.99%	81.63%	24.12%	32.04%	16.68%	17.53%	16.72%	17.28%	-
Other Operating Expenses	0	0	0	0	0	0	0	71.1M	0	0
Operating Income	814.9M▲ 0%	805.4M▼ 1.2%	-187.6M▼ 123.3%	593.6M▲ 416.4%	555.9M▼ 6.4%	979.7M▲ 76.2%	1.18B▲ 20.9%	1.38B▲ 16.2%	1.49B▲ 8.4%	1.44B▲ 0%
Operating Margin %	47.23%	49.48%	-12.95%	40.02%	32.98%	50.6%	50.91%	47.86%	46.89%	45.29%
Operating Income Growth %	-23.25%	-1.17%	-123.29%	416.42%	-6.35%	76.24%	20.95%	16.21%	8.39%	-
EBITDA	845.9M	841.3M	-141.7M	643.5M	605.8M	1.03B	1.24B	1.45B	1.58B	1.56B
EBITDA Margin %	49.03%	51.68%	-9.78%	43.38%	35.94%	53.25%	53.19%	50.38%	49.58%	49.08%
EBITDA Growth %	-22.63%	-0.54%	-116.84%	554.13%	-5.86%	70.19%	20.09%	17.07%	8.87%	9.06%
D&A (Non-Cash Add-back)	31M	35.9M	45.9M	49.9M	49.9M	51.3M	53.2M	72.5M	85.6M	120.2M
EBIT	1.02B	802.5M	-120.8M	596.4M	686.9M	989M	1.33B	1.58B	1.73B	1.3B
Net Interest Income	1.9M	14.7M	0	5.1M	-1.9M	12.8M	103.4M	156.2M	172.5M	127.5M
Interest Income	10.9M	28.6M	44.2M	28.6M	16.7M	45.2M	162.7M	199.1M	192M	182.7M
Interest Expense	9M	13.9M	44.2M	23.5M	18.6M	32.4M	59.3M	42.9M	19.5M	10.4M
Other Income/Expense	-45.4M	-46.5M	22.6M	45.3M	38M	-29.1M	89.4M	162M	221.4M	173.2M
Pretax Income	769.5M▲ 0%	758.9M▼ 1.4%	-165M▼ 121.7%	638.9M▲ 487.2%	593.9M▼ 7.0%	950.6M▲ 60.1%	1.27B▲ 34.1%	1.54B▲ 20.8%	1.71B▲ 11.4%	1.61B▲ 0%
Pretax Margin %	44.6%	46.62%	-11.39%	43.07%	35.24%	49.09%	54.75%	53.49%	53.85%	50.75%
Income Tax	351.6M	169.7M	-60.5M	124.1M	118.1M	223.3M	289.5M	343.9M	379.2M	234.5M
Effective Tax Rate %	45.69%	22.36%	36.67%	19.42%	19.89%	23.49%	22.72%	22.35%	22.12%	14.58%
Net Income	417.9M▲ 0%	589.2M▲ 41.0%	-104.5M▼ 117.7%	514.8M▲ 592.6%	475.8M▼ 7.6%	727.3M▲ 52.9%	984.8M▲ 35.4%	1.2B▲ 21.4%	1.33B▲ 11.7%	1.29B▲ 0%
Net Margin %	24.22%	36.2%	-7.21%	34.71%	28.23%	37.56%	42.31%	41.53%	41.94%	40.61%
Net Income Growth %	-41.45%	40.99%	-117.74%	592.63%	-7.58%	52.86%	35.4%	21.35%	11.68%	6.34%
Net Income (Continuing)	417.9M	589.2M	-104.5M	514.8M	475.8M	727.3M	984.8M	1.2B	1.33B	1.29B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	9.31▲ 0%	13.39▲ 43.8%	-2.39▼ 117.8%	11.54▲ 582.8%	10.06▼ 12.8%	15.00▲ 49.1%	19.81▲ 32.1%	24.64▲ 24.4%	27.86▲ 13.1%	27.28▲ 0%
EPS Growth %	-38.95%	43.82%	-117.85%	582.85%	-12.83%	49.11%	32.07%	24.38%	13.07%	7.94%
EPS (Basic)	9.50	13.54	-2.39	11.65	10.60	15.98	21.04	26.44	30.13	-
Diluted Shares Outstanding	44.9M	44M	43.8M	44.6M	47.3M	48.5M	49.7M	48.5M	47.9M	47.2M
Basic Shares Outstanding	44M	43.5M	43.8M	44.2M	44.9M	45.5M	46.8M	45.2M	44.3M	43.5M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

UTHR Balance Sheet

United Therapeutics Corporation (UTHR) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	1.45B	1.77B	1.86B	2.17B	2.32B	3.38B	3.55B	3.87B	3.7B	2.87B
Cash & Short-Term Investments	927.4M	1.42B	1.49B	1.83B	1.93B	2.84B	2.99B	3.27B	1.56B	1.28B
Cash Only	705.1M	669.2M	738.4M	738.7M	894.8M	961.2M	1.21B	1.7B	1.56B	1.28B
Short-Term Investments	222.3M	746.7M	747.5M	1.1B	1.04B	1.88B	1.79B	1.57B	0	0
Accounts Receivable	297.1M	175.7M	151.4M	157.4M	198.7M	220.4M	278.9M	279.3M	350.2M	312M
Days Sales Outstanding	62.85	39.4	38.14	38.73	43.03	41.55	43.74	35.43	40.16	38.55
Inventory	107.9M	101M	93.4M	86.5M	93.8M	102M	111.8M	157.9M	183.1M	178.3M
Days Inventory Outstanding	372.6	185.53	289.89	292.07	279.49	253.78	158.47	186.09	173.86	151.71
Other Current Assets	115.5M	75.4M	-633.7M	88.3M	100.4M	219.2M	166.2M	169.7M	1.61B	1.1B
Total Non-Current Assets	1.43B	1.63B	2.05B	2.45B	2.85B	2.66B	3.62B	3.49B	4.18B	3.84B
Property, Plant & Equipment	545.7M	699.7M	738.5M	731.6M	780.9M	861.5M	1.05B	1.22B	1.73B	1.84B
Fixed Asset Turnover	3.16x	2.33x	1.96x	2.03x	2.16x	2.25x	2.23x	2.35x	1.84x	1.95x
Goodwill	13.7M	31.5M	28M	28M	28M	28M	33.7M	32.3M	0	0
Intangible Assets	31.9M	139.3M	130.3M	130.1M	16.6M	16.5M	80.5M	79.6M	116.5M	0
Long-Term Investments	502.7M	442.6M	767.5M	1.15B	1.65B	1.32B	1.91B	1.48B	1.78B	6.67B
Other Non-Current Assets	224.1M	224.2M	154.6M	169.9M	108.2M	114.3M	151.8M	222.1M	196.9M	837M
Total Assets	2.88B▲ 0%	3.4B▲ 18.1%	3.91B▲ 15.1%	4.62B▲ 17.9%	5.17B▲ 12.0%	6.04B▲ 16.9%	7.17B▲ 18.6%	7.36B▲ 2.7%	7.88B▲ 7.0%	6.71B▲ 0%
Asset Turnover	0.60x	0.48x	0.37x	0.32x	0.33x	0.32x	0.32x	0.39x	0.40x	0.42x
Asset Growth %	23.81%	18.11%	15.07%	17.93%	12.01%	16.94%	18.57%	2.75%	7.01%	14.53%
Total Current Liabilities	444.7M	276.6M	463M	323.3M	305.4M	343.2M	804.4M	738.1M	560.6M	599.1M
Accounts Payable	8.4M	23.1M	9.9M	4.1M	3.8M	4.1M	5.6M	6M	0	0
Days Payables Outstanding	29.01	42.43	30.73	13.84	11.32	10.2	7.94	7.07	-	193.1
Short-Term Debt	0	0	250M	0	0	0	400M	300M	0	0
Deferred Revenue (Current)	0	0	163.5M	0	0	0	0	0	0	0
Other Current Liabilities	401.7M	215.6M	-141.4M	20.4M	248M	13M	40.5M	432.1M	560.6M	599.1M
Current Ratio	3.26x	6.39x	4.03x	6.70x	7.61x	9.85x	4.41x	5.25x	6.60x	6.60x
Quick Ratio	3.01x	6.03x	3.83x	6.44x	7.30x	9.55x	4.28x	5.03x	6.28x	6.28x
Cash Conversion Cycle	406.44	182.49	297.31	316.96	311.19	285.13	194.27	214.45	-	-2.84
Total Non-Current Liabilities	313.7M	316.6M	670M	896.5M	904.8M	904.6M	377.8M	181.9M	223.2M	214M
Long-Term Debt	250M	250M	600M	800M	800M	800M	300M	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	63.7M	66.6M	70M	96.5M	104.8M	104.6M	77.8M	181.9M	223.2M	859.1M
Total Liabilities	777.6M	612.4M	1.13B	1.22B	1.21B	1.25B	1.18B	920M	783.8M	813.1M
Total Debt	250M	250M	850M	800M	800M	800M	700M	300M	0	0
Net Debt	-455.1M	-419.2M	111.6M	61.3M	-94.8M	-161.2M	-507.7M	-1.4B	-1.56B	-1.28B
Debt / Equity	0.12x	0.09x	0.31x	0.24x	0.20x	0.17x	0.12x	0.05x	-	0.00x
Debt / EBITDA	0.30x	0.30x	-	1.24x	1.32x	0.78x	0.57x	0.21x	-	0.00x
Net Debt / EBITDA	-0.54x	-0.50x	-	0.10x	-0.16x	-0.16x	-0.41x	-0.96x	-0.99x	-0.99x
Interest Coverage	113.60x	57.73x	-2.73x	25.38x	36.93x	30.52x	22.49x	36.87x	88.89x	125.37x
Total Equity	2.1B▲ 0%	2.79B▲ 32.7%	2.78B▼ 0.3%	3.4B▲ 22.1%	3.96B▲ 16.6%	4.8B▲ 21.2%	5.98B▲ 24.8%	6.44B▲ 7.7%	7.1B▲ 10.1%	5.9B▲ 0%
Equity Growth %	12.87%	32.68%	-0.29%	22.11%	16.6%	21.16%	24.77%	7.67%	10.12%	30.74%
Book Value per Share	46.81	63.38	63.48	76.13	83.70	98.90	120.42	132.87	148.15	125.02
Total Shareholders' Equity	2.1B	2.79B	2.78B	3.4B	3.96B	4.8B	5.98B	6.44B	7.1B	5.9B
Common Stock	700K	700K	700K	700K	700K	700K	700K	800K	800K	800K
Retained Earnings	2.85B	3.43B	3.33B	3.84B	4.32B	5.04B	6.03B	7.22B	8.56B	8.83B
Treasury Stock	-2.58B	-2.58B	-2.58B	-2.58B	-2.58B	-2.58B	-2.58B	-3.47B	-4.26B	0
Accumulated OCI	-19.6M	-7.9M	-14.2M	-14.2M	-23M	-55.5M	-12.8M	-3.4M	900K	-10.2M
Minority Interest	0	0	0	0	0	0	0	0	0	0

UTHR Cash Flow Statement

United Therapeutics Corporation (UTHR) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	474.2M	778.4M	-206.6M	755.7M	598.2M	802.5M	978M	1.33B	1.56B	1.56B
Operating CF Margin %	27.49%	47.82%	-14.26%	50.95%	35.49%	41.45%	42.02%	46.12%	49.05%	-
Operating CF Growth %	-26.32%	64.15%	-126.54%	465.78%	-20.84%	34.15%	21.87%	35.7%	17.64%	33.5%
Net Income	417.9M	589.2M	-104.5M	514.8M	475.8M	727.3M	984.8M	1.2B	1.33B	1.29B
Depreciation & Amortization	31M	35.9M	45.9M	49.9M	49.9M	51.3M	53.2M	72.5M	85.6M	88.4M
Stock-Based Compensation	73.5M	-26.4M	45.4M	163.8M	138.5M	106.8M	39.1M	144M	147.7M	149.8M
Deferred Taxes	0	0	0	0	0	0	0	0	97.7M	123.6M
Other Non-Cash Items	30.2M	55.3M	-15.1M	-35.9M	108.2M	58.3M	-1.3M	-24.3M	2M	98.6M
Working Capital Changes	-78.4M	124.4M	-178.3M	63.1M	-174.2M	-141.2M	-97.8M	-60.2M	-106.4M	-184.4M
Change in Receivables	-82.7M	121.4M	24.4M	-6M	-41.3M	-21.7M	-58.5M	-400K	-70.9M	10M
Change in Inventory	-500K	9.3M	12.9M	10.3M	-7.5M	-13.4M	-13.6M	-46.9M	-52.6M	-81.5M
Change in Payables	66.2M	0	0	0	0	0	0	0	97.9M	85.2M
Cash from Investing	-835.6M	-820.6M	-335.4M	-738.5M	-486.9M	-811.5M	-719.6M	417.2M	-551.3M	357.1M
Capital Expenditures	-86.3M	-184.4M	-83.7M	-59.3M	-120.8M	-138.8M	-230.4M	-246.5M	-520.5M	-546.4M
CapEx % of Revenue	5%	11.33%	5.78%	4%	7.17%	7.17%	9.9%	8.57%	16.35%	-
Acquisitions	-60.3M	-129.1M	-20.5M	0	0	-1.5M	-89.2M	-30.5M	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	8.3M	-46M	0	2.4M	0	3.5M	-23M	-28.5M	1.85B	3.16B
Cash from Financing	43.3M	6.3M	611.2M	-16.9M	44.8M	75.4M	-11.9M	-1.25B	-1.15B	-2.54B
Debt Issued (Net)	250M	0	600M	-50M	0	0	-100M	-400M	-300M	-200M
Equity Issued (Net)	-250M	0	-2.1M	-3.7M	-10.8M	-11.4M	-13.8M	-1.01B	-816.9M	-816.9M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-250M	0	-2.1M	-3.7M	-10.8M	-11.4M	-13.8M	-1.01B	-1B	-2.5B
Other Financing	43.3M	6.3M	13.3M	36.8M	55.6M	86.8M	101.9M	157.4M	-33.1M	-1.52B
Net Change in Cash	-317.9M▲ 0%	-35.9M▲ 88.7%	69.2M▲ 292.8%	300K▼ 99.6%	156.1M▲ 51933.3%	66.4M▼ 57.5%	246.5M▲ 271.2%	489.5M▲ 98.6%	-140.1M▼ 128.6%	-620.2M▲ 0%
Free Cash Flow	387.9M▲ 0%	594M▲ 53.1%	-290.3M▼ 148.9%	696.4M▲ 339.9%	477.4M▼ 31.4%	663.7M▲ 39.0%	747.6M▲ 12.6%	1.08B▲ 44.5%	1.04B▼ 3.7%	1.02B▲ 0%
FCF Margin %	22.48%	36.49%	-20.04%	46.95%	28.32%	34.28%	32.12%	37.55%	32.7%	32.08%
FCF Growth %	-35.39%	53.13%	-148.87%	339.89%	-31.45%	39.02%	12.64%	44.54%	-3.69%	-9.9%
FCF per Share	8.64	13.50	-6.63	15.61	10.09	13.68	15.04	22.28	21.73	21.73
FCF Conversion (FCF/Net Income)	1.13x	1.32x	1.98x	1.47x	1.26x	1.10x	0.99x	1.11x	1.17x	0.79x
Interest Paid	7.5M	9.4M	41M	20.7M	16.2M	29.1M	56M	40.2M	13.5M	8.1M
Taxes Paid	346.9M	102.7M	120.2M	92.8M	153.3M	275.7M	332.5M	400.6M	313.3M	312.8M

UTHR Key Ratios

United Therapeutics Corporation (UTHR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	21.08%	24.1%	-3.75%	16.67%	12.94%	16.61%	18.27%	19.23%	19.71%	19.24%
Return on Invested Capital (ROIC)	49.17%	30.08%	-5.35%	14.03%	11.39%	17.29%	17.58%	19.63%	21.15%	21.15%
Gross Margin	93.87%	87.79%	91.88%	92.71%	92.73%	92.42%	88.94%	89.24%	87.92%	86.58%
Net Margin	24.22%	36.2%	-7.21%	34.71%	28.23%	37.56%	42.31%	41.53%	41.94%	40.61%
Debt / Equity	0.12x	0.09x	0.31x	0.24x	0.20x	0.17x	0.12x	0.05x	-	0.00x
Interest Coverage	113.60x	57.73x	-2.73x	25.38x	36.93x	30.52x	22.49x	36.87x	88.89x	125.37x
FCF Conversion	1.13x	1.32x	1.98x	1.47x	1.26x	1.10x	0.99x	1.11x	1.17x	0.79x
Revenue Growth	7.91%	-5.65%	-11%	2.38%	13.63%	14.88%	20.2%	23.63%	10.61%	5.87%

UTHR SEC Filings & Documents

United Therapeutics Corporation (UTHR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

Mar 30, 2026·SEC

Material company update

Mar 9, 2026·SEC

10-K Annual Reports

FY 2026

Feb 25, 2026·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Oct 29, 2025·SEC

FY 2025

Jul 30, 2025·SEC

UTHR Frequently Asked Questions

United Therapeutics Corporation (UTHR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

United Therapeutics Corporation (UTHR) reported $3.17B in revenue for fiscal year 2025. This represents a 3169700% increase from $0.1M in 1998.

United Therapeutics Corporation (UTHR) grew revenue by 10.6% over the past year. This is steady growth.

Yes, United Therapeutics Corporation (UTHR) is profitable, generating $1.29B in net income for fiscal year 2025 (41.9% net margin).

Dividend & Returns

United Therapeutics Corporation (UTHR) has a return on equity (ROE) of 19.7%. This is reasonable for most industries.

United Therapeutics Corporation (UTHR) generated $1.02B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More UTHR

United Therapeutics Corporation (UTHR) financial analysis — history, returns, DCA and operating performance tools

Full UTHR Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

United Therapeutics Corporation(UTHR)Earnings, Financials & Key Ratios

UTHR Key Insights

✓Strengths

✗Weaknesses

UTHR Price & Volume

UTHR Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

UTHR Recent Earnings

UTHR Peer Comparison

Compare UTHR vs Peers

vs IDYA

vs MCK

Compare Top 5

UTHR Income Statement

UTHR Balance Sheet

UTHR Cash Flow Statement

UTHR Key Ratios

UTHR SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

UTHR Frequently Asked Questions

Explore More UTHR

Full UTHR Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation